Replies to post #84767 on Biotech Values

[taLuis]

ACHN

They have approximately six month's of $cash left, at their current burn rate. That may be just enough for their Phase 1b PoC data due in 1Q2010. Are you assuming a "lucrative" partner will come to the rescue at that point? It won't leave them much negotiating room, if so.

Is there a possibility of them doing a PIPE before then?

[drbio45]

thank you senior

[bxjwn9ru]

ACHN

I am as bullish on it as I've ever been. ACHN represents about 17% of my biofolio at current market value and is one of my largest holdings.

It's official - You Have My Attention. Looks like this will be my assignment for the weekend. Watch out for a possible big buyer on Monday morning. j/k

[read_this_n0w]

Anyone following MYRX and drug Azixa ?

Looking for other comments or dd expectations


The most important opportunity is cancer treatment, through a drug called Azixa. We expect Phase II results in late 2009. Azixa is currently being tested on an aggressive type of brain cancer and a type of aggressive melanoma that has metastasized into the brain. However, the technology may prove effective for a variety of tumor types. The reason for focusing on the brain is that the drug demonstrated an ability to naturally concentrate itself there, providing greater therapeutic benefits